Genetico’s RAS Results for 9M 2025

Genetico Center for Genetics and Reproductive Medicine (MOEX: GECO) has published its operating results for the 9 months of 2025, prepared in accordance with Russian Accounting Standards (RAS).

For 9M 2025, the Company's revenue grew by 37.4% compared to the same period of the previous year, reaching RUB 408.1 million. Gross profit increased by 8.2% to RUB 92.9 million.

EBITDA amounted to RUB 21.2 million, which is RUB 25.7 million lower than a year earlier. The decrease in this indicator is associated with an increase in commercial expenses aimed at the Company's development and an increase in cost of sales related to the development of new products.

In June 2025, the Company fully repaid its issued bonds and currently has no loan or borrowing obligations.

Genetico Center, a resident of Skolkovo and MedTech Technopark, is part of the Artgen Biotech Group (MOEX: ABIO). The Company operates in the field of medical genetics and genetic research, implementing innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases into healthcare practice.

Key events in 9M 2025:

The number of genetic tests (+32%) and consultations (+13%) increased compared to the previous period.
Genetico received a patent for the Onconetix panel for genetic testing of tumors and selection of targeted therapy for oncological diseases.
Genetico invested RUB 20 million in Retinostar, a developer of first-in-class gene therapy treatments for orphan eye diseases.
Genetico fully repaid its bond loan in the amount of RUB 145 million.
Genetico's shares were admitted to trading on the SPB Exchange, including during the additional session.
Genetico completed a private placement of 7 million shares in favor of companies within the Artgen Biotech Group.
The Board of Directors of Genetico appointed a new head of the Company.

Key Indicators of P&L Statement for 9M 2025

RUB, thousands	January – September 2025	January – September 2024	% change
Revenue	408 140	297 009	37,4%
Cost of sales	-315 212	-211 163	49,3%
Gross profit (loss)	92 928	85 846	8,2%
Commercial expenses	-54 646	-37 860	44,3%
Management expenses	-59 865	-37 242	60,7%
Profit (loss) from sales	-21 583	10 744	-300,9%
Interest receivable	2 312	938	146,5%
Interest payable	-6 443	-22 489	-71,4%
Other income and (expenses), net	2 602	5 389	-51,7%
Net profit (loss)	-23 112	-5 418	-326,6%
EBITDA¹	21 202	46 934	-54,8%
EBITDA margin, %	5,2%	15,8%

¹ EBITDA — earnings before interest, taxes, depreciation and amortization. This indicator reflects the operating cash flow of the Company.

Key Balance Sheet Indicators as of 9M 2025

*RUB, thousands*	September 30, 2025	December 31, 2024	*% change*
ASSETS
Intangible assets + Fixed assets	649 177	659 520	-1,6%
Stocks	127 516	118 628	7,5%
Accounts receivable	92 530	68 522	35,0%
Financial investments	44 980	30 500	47,5%
Cash and cash equivalents	13 492	3 571	277,8%
TOTAL ASSETS	927 800	881 002	5,3%
LIABILITIES
Equity and reserves	815 264	600 376	35,8%
Long-term liabilities	38 482	45 101	-2,7%
Current liabilities	74 054	235 525	-69,3%
TOTAL LIABILITIES	927 800	881 002	5,3%

The financial statements of Genetico PJSC for 9M 2025 under RAS are available on the corporate website. For further information, please contact krasotkin@nextgene.ru